Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.
William J ChapinWei-Ting HwangThomas Benjamin KarasicAnne Marie McCarthyDavid E KaplanPublished in: Cancer medicine (2022)
In patients with HCC and Child-Pugh B cirrhosis, nivolumab treatment may be associated with improved overall survival and improved tolerability compared to sorafenib and should be considered for the first systemic treatment in this population.